Kirkpatrick, J. P., Rich, J. N., Vredenburgh, J. J., Desjardins, A., Quinn, J. A., Gururangan, S., … Reardon, D. A. (2008). Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). JOURNAL OF CLINICAL ONCOLOGY, 26(15).

Kirkpatrick, J. P., J. N. Rich, J. J. Vredenburgh, A. Desjardins, J. A. Quinn, S. Gururangan, S. Sathornsumetee, M. J. Egorin, H. S. Friedman, and D. A. Reardon. “Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).” JOURNAL OF CLINICAL ONCOLOGY 26, no. 15 (May 20, 2008).

Kirkpatrick JP, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, et al. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). JOURNAL OF CLINICAL ONCOLOGY. 2008 May 20;26(15).

Kirkpatrick, J. P., et al. “Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG).” JOURNAL OF CLINICAL ONCOLOGY, vol. 26, no. 15, AMER SOC CLINICAL ONCOLOGY, May 2008.

Kirkpatrick JP, Rich JN, Vredenburgh JJ, Desjardins A, Quinn JA, Gururangan S, Sathornsumetee S, Egorin MJ, Friedman HS, Reardon DA. Final report: Phase I trial of imatinib mesylate, hydroxyurea, and vatalanib for patients with recurrent malignant glioma (MG). JOURNAL OF CLINICAL ONCOLOGY. AMER SOC CLINICAL ONCOLOGY; 2008 May 20;26(15).